IL141423A - Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof - Google Patents

Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Info

Publication number
IL141423A
IL141423A IL14142399A IL14142399A IL141423A IL 141423 A IL141423 A IL 141423A IL 14142399 A IL14142399 A IL 14142399A IL 14142399 A IL14142399 A IL 14142399A IL 141423 A IL141423 A IL 141423A
Authority
IL
Israel
Prior art keywords
processes
alendronate sodium
manufacture
pharmaceutical compositions
hydrate forms
Prior art date
Application number
IL14142399A
Other languages
English (en)
Other versions
IL141423A0 (en
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL141423A0 publication Critical patent/IL141423A0/xx
Publication of IL141423A publication Critical patent/IL141423A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL14142399A 1998-08-27 1999-08-27 Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof IL141423A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
IL141423A0 IL141423A0 (en) 2002-03-10
IL141423A true IL141423A (en) 2005-09-25

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14142399A IL141423A (en) 1998-08-27 1999-08-27 Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Country Status (30)

Country Link
US (2) US6281381B1 (et)
EP (1) EP1107974B1 (et)
JP (2) JP2002523514A (et)
KR (2) KR20070034132A (et)
AT (1) ATE334993T1 (et)
AU (1) AU5698899A (et)
BG (1) BG65329B1 (et)
BR (1) BR9913472A (et)
CA (1) CA2341459A1 (et)
CZ (1) CZ2001629A3 (et)
DE (1) DE69932620T2 (et)
DK (1) DK1107974T3 (et)
EA (1) EA002739B1 (et)
EE (1) EE04552B1 (et)
ES (1) ES2270613T3 (et)
HR (1) HRP20010129A2 (et)
HU (1) HUP0203078A3 (et)
IL (1) IL141423A (et)
IS (1) IS5864A (et)
LT (1) LT4888B (et)
LV (1) LV12720B (et)
NO (1) NO20010957L (et)
NZ (1) NZ510682A (et)
PL (1) PL346347A1 (et)
PT (1) PT1107974E (et)
RO (1) RO122854B1 (et)
SI (1) SI20581B (et)
SK (1) SK2482001A3 (et)
WO (1) WO2000012517A1 (et)
YU (1) YU14701A (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451881A1 (fr) * 2001-07-16 2003-01-30 Universite Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
NZ587774A (en) 2004-05-24 2012-03-30 Warner Chilcott Co Llc Enteric solid oral dosage form of bisphosphonate containing a chelating agent
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
ES2442257T3 (es) * 2006-10-27 2014-02-10 Signal Pharmaceuticals Llc Formas sólidas que comprenden 4-[9-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-ciclohexan-1-ol, sus composiciones y sus usos
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
AU5886096A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2221844A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
NO20010957L (no) 2001-04-26
LV12720B (en) 2002-02-20
SK2482001A3 (en) 2002-01-07
PL346347A1 (en) 2002-02-11
HRP20010129A2 (en) 2005-04-30
US20030065214A1 (en) 2003-04-03
CA2341459A1 (en) 2000-03-09
DE69932620T2 (de) 2006-12-14
LV12720A (lv) 2001-09-20
CZ2001629A3 (cs) 2001-08-15
BG105292A (en) 2001-12-29
US6696601B2 (en) 2004-02-24
BR9913472A (pt) 2002-03-05
BG65329B1 (bg) 2008-02-29
ES2270613T3 (es) 2007-04-01
KR20010079701A (ko) 2001-08-22
EE04552B1 (et) 2005-10-17
ATE334993T1 (de) 2006-08-15
EP1107974A4 (en) 2001-09-26
HUP0203078A2 (hu) 2003-01-28
PT1107974E (pt) 2006-10-31
AU5698899A (en) 2000-03-21
KR20070034132A (ko) 2007-03-27
SI20581A (sl) 2001-12-31
NO20010957D0 (no) 2001-02-26
NZ510682A (en) 2003-09-26
EE200100126A (et) 2002-06-17
IL141423A0 (en) 2002-03-10
IS5864A (is) 2001-02-26
US6281381B1 (en) 2001-08-28
WO2000012517A9 (en) 2000-07-13
JP2002523514A (ja) 2002-07-30
EA002739B1 (ru) 2002-08-29
SI20581B (sl) 2008-06-30
DK1107974T3 (da) 2006-10-30
WO2000012517A1 (en) 2000-03-09
DE69932620D1 (de) 2006-09-14
YU14701A (sh) 2003-01-31
EP1107974B1 (en) 2006-08-02
LT4888B (lt) 2002-02-25
RO122854B1 (ro) 2010-03-30
EA200100184A1 (ru) 2001-10-22
EP1107974A1 (en) 2001-06-20
LT2001016A (en) 2001-10-25
HUP0203078A3 (en) 2005-01-28
JP2009143955A (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
IL141423A0 (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
DE60038038D1 (en) Phosphonatverbindungen
NZ272610A (en) The manufacture of dispersible tablets containing fluoxetine by direct compression
ZA200001342B (en) Implant for interconnecting two bone fragments.
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
MY119970A (en) Method of fertilizing an avian egg in the shell
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
HUP0102813A3 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
AU2003268398A1 (en) Sodium glyphosate compositions and process for their preparation
ZA200101451B (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.
PL346536A1 (en) Process for the preparation of calcium hydroxyalkane sulphonates
HUP9801781A3 (en) Process for producing indolil-methane compounds and pharmaceutical compositions for inhibiting transcriptase (rt) enzyme comprising the same compounds
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees